Physician profile
Madison Masters
NPI 1477120426
$7,006.53
in general payments reported to CMS, 2019-2025
32 companies · $1,824 in 2025
The $1,824 reported for 2025 was more than what 92% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,335 · 2023: $1,572 · 2024: $2,276 · 2025: $1,824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,332 · Education: $340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,331.56 |
| Education | $340.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,175.66 | 2022-2025 | |
| Janssen Biotech, INC. | $710.07 | 2022-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $655.40 | 2022-2024 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $634.56 | 2022-2024 | Xifaxan, Trulance |
| Ardelyx, INC. | $439.77 | 2022-2024 | Ibsrela |
| Ucb, INC. | $257.21 | 2024-2025 | Bimzelx |
| E.R. Squibb & Sons, L.L.C. | $248.15 | 2024-2025 | Sotyktu |
| Genzyme Corporation | $217.28 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $202.60 | 2022-2024 | Dupixent |
| Pfizer INC. | $201.89 | 2023-2025 | |
| Phathom Pharmaceuticals, INC. | $193.65 | 2024 | Voquezna |
| Intercept Pharmaceuticals, INC. | $168.11 | 2022 | |
| Gilead Sciences, INC. | $152.64 | 2023-2024 | Vemlidy |
| Amgen INC. | $139.91 | 2025 | Otezla |
| Lilly USA, LLC | $107.29 | 2024-2025 | Ebglyss, Taltz |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $81.37 | 2024-2025 | |
| Nestle Healthcare Nutrition INC. | $77.41 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $75.23 | 2024 | |
| Ironwood Pharmaceuticals, INC | $37.17 | 2023-2024 | Linzess |
| Galderma Laboratories, L.P. | $19.82 | 2025 | Nemluvio |
| Botanix Sb INC | $19.78 | 2025 | Sofdra |
| Braintree Laboratories, INC. | $19.41 | 2024 | Sutab, Suflave |
| Qol Medical, LLC | $19.21 | 2022 | |
| Celltrion USA INC. | $18.86 | 2024 | Zymfentra |
| Phadia US INC. | $18.50 | 2023 | Immunocap |
| Arcutis Biotherapeutics, INC. | $18.00 | 2025 | Zoryve |
| Paratek Pharmaceuticals, INC. | $17.50 | 2025 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $17.33 | 2024 | |
| Leo Pharma INC. | $16.77 | 2025 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.71 | 2023 | Cyltezo |
| Madrigal Pharmaceuticals | $15.66 | 2024 | Resmetirom |
| Kyowa Kirin, INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Madison Masters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.